BR112013000345A2 - composições antigênicas para vírus sincicial respiratório e métodos - Google Patents
composições antigênicas para vírus sincicial respiratório e métodosInfo
- Publication number
- BR112013000345A2 BR112013000345A2 BR112013000345A BR112013000345A BR112013000345A2 BR 112013000345 A2 BR112013000345 A2 BR 112013000345A2 BR 112013000345 A BR112013000345 A BR 112013000345A BR 112013000345 A BR112013000345 A BR 112013000345A BR 112013000345 A2 BR112013000345 A2 BR 112013000345A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- respiratory syncytial
- syncytial virus
- multilayer films
- antigenic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/14—Peptides being immobilised on, or in, an inorganic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
composições antigênicas para vírus sincicial respiratório e métodos. filmes multicamadas compreendem epítopos de polipeptídeo do rsv. os filmes multicamadas são capazes de induzir uma resposta imunológica em um hospedeiro via administração destes ao hospedeiro. os filmes multicamadas compreendem pelo menos um peptídeo desenvolvido que inclui ou um mais epítopos de polipeptídeo do rsv. especificamente, os filmes multicamadas incluem dois epítopos de polipeptídeo do rsv, tal como um epítopo que induz uma resposta de célulast específica, tal como uma resposta de células-t citotóxicas, e um epítopo que induz uma resposta de anticorpos específica.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36202910P | 2010-07-07 | 2010-07-07 | |
US61/362,029 | 2010-07-07 | ||
US201161485669P | 2011-05-13 | 2011-05-13 | |
US61/485,669 | 2011-05-13 | ||
PCT/US2011/043136 WO2012006395A1 (en) | 2010-07-07 | 2011-07-07 | Respiratory syncytial virus antigenic compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013000345A2 true BR112013000345A2 (pt) | 2016-05-31 |
BR112013000345B1 BR112013000345B1 (pt) | 2021-11-23 |
Family
ID=45438747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013000345-6A BR112013000345B1 (pt) | 2010-07-07 | 2011-07-07 | Composição compreendendo partículas contendo epítopos de rsv |
Country Status (13)
Country | Link |
---|---|
US (1) | US9487593B2 (pt) |
EP (1) | EP2590675B1 (pt) |
JP (1) | JP5890407B2 (pt) |
CN (2) | CN103037898B (pt) |
AU (1) | AU2011276251B2 (pt) |
BR (1) | BR112013000345B1 (pt) |
CA (1) | CA2799934C (pt) |
DK (1) | DK2590675T3 (pt) |
ES (1) | ES2688993T3 (pt) |
IL (1) | IL222723B (pt) |
MX (1) | MX340796B (pt) |
RU (1) | RU2609661C2 (pt) |
WO (1) | WO2012006395A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8883717B2 (en) | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
US9433671B2 (en) | 2012-03-30 | 2016-09-06 | Artificial Cell Technologies, Inc. | Anti-malaria compositions and methods |
EA201891945A3 (ru) | 2012-08-01 | 2019-05-31 | Бавариан Нордик А/С | Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv) |
DK3033102T4 (da) * | 2013-08-13 | 2024-02-26 | Univ Northwestern | Peptidkonjugerede partikler |
US9975066B2 (en) | 2014-05-27 | 2018-05-22 | Artificial Cell Technologies, Inc. | Automated layer by layer construction of multilayer coated cores by TFF |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
MX2018003103A (es) | 2015-09-16 | 2018-06-11 | Artificial Cell Tech Inc | Composiciones y procedimientos contra la malaria. |
US20170230649A1 (en) * | 2016-02-05 | 2017-08-10 | Qualcomm Incorporated | Calibration of hybrid auto focus (af) imaging systems |
CN115947873A (zh) | 2017-04-04 | 2023-04-11 | 华盛顿大学 | 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途 |
US11773143B2 (en) | 2017-10-13 | 2023-10-03 | Trellis Bioscience, Llc | Conformational epitopes in respiratory syncytial virus G protein central conserved region |
EP3758747A1 (en) | 2018-02-28 | 2021-01-06 | University of Washington | Self-asssembling nanostructure vaccines |
US20230414526A1 (en) * | 2022-03-29 | 2023-12-28 | Artificial Cell Technologies, Inc. | Respiratory syncytial virus antigenic compositions and methods |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4053587B2 (ja) * | 1993-08-06 | 2008-02-27 | サノフィ パスツール リミテッド | 不活性化レスピラトリーシンシシャルウイルスワクチン |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
WO1996006112A1 (en) | 1994-08-25 | 1996-02-29 | Instituut Voor Veehouderij En Diergezondheid (Id-Dlo) | Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection |
FR2726471B1 (fr) | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
AUPO026596A0 (en) | 1996-06-05 | 1996-06-27 | Biomolecular Research Institute Limited | Viral peptide |
AU2002224416A1 (en) | 2000-10-18 | 2002-04-29 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Compositions and methods for modulating RSV infection and immunity |
FR2819810B1 (fr) | 2001-01-23 | 2004-05-28 | Pf Medicament | Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin |
AUPR520201A0 (en) | 2001-05-23 | 2001-06-14 | Commonwealth Scientific And Industrial Research Organisation | Antiviral compounds |
JP3997930B2 (ja) | 2003-02-27 | 2007-10-24 | 富士ゼロックス株式会社 | カーボンナノチューブの製造装置および製造方法 |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
US7348399B2 (en) | 2003-08-29 | 2008-03-25 | Louisiana Tech University Foundation, Inc. | Nanofabricated polypeptide multilayer films, coatings, and microcapsules |
US7615530B2 (en) | 2003-08-29 | 2009-11-10 | Artificial Cell Technologies, Inc. | Immunogenic compositions and methods of use |
WO2006023029A2 (en) * | 2004-06-16 | 2006-03-02 | The Johns Hopkins University | The cysteine-rich region of respiratory syncytial virus and methods of use therefor |
US20080131450A1 (en) | 2004-07-23 | 2008-06-05 | Pierre Fabre Medicament | Immunogenic complexes, preparation method thereof and use of same in pharmaceutical compositions |
US20080171070A1 (en) * | 2005-01-31 | 2008-07-17 | Pierre Schaaf | Polyelectrolyte Multilayer Film, Preparation And Uses Thereof |
US20090220537A1 (en) * | 2005-04-12 | 2009-09-03 | The University Of Queensland | Vaccine delivery system |
US20080020402A1 (en) | 2005-10-25 | 2008-01-24 | Haynie Donald T | Polypeptide multilayer films and methods |
EP1972348A1 (en) | 2007-03-14 | 2008-09-24 | Pierre Fabre Medicament | Novel vaccine composition for the treatment of respiratory infectious diseases |
EP2181121A4 (en) | 2007-03-21 | 2012-07-11 | Id Biomedical Corp Quebec | CHIMÄRE ANTIGENE |
US7723294B2 (en) * | 2007-04-02 | 2010-05-25 | Artificial Cell Technologies, Inc. | Polypeptide films and methods |
EP2197457A4 (en) * | 2007-09-26 | 2010-10-27 | Aparna Biosciences | THERAPEUTIC VACCINE POLYELECTROLYTE NANOPARTICLE COMPOSITIONS |
EP2058002A1 (en) * | 2007-10-31 | 2009-05-13 | Bestewil Holding B.V. | Reconstituted respiratory syncytial virus membranes and use as respiratory syncytial virus vaccine |
BRPI0915960A2 (pt) | 2008-07-18 | 2019-09-24 | Id Biomedical Corp | antígenos de polipeptídeos do vírus sincicial respiratório qimérico |
WO2010075491A2 (en) | 2008-12-24 | 2010-07-01 | University Of Rochester | Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins |
AU2010279492B2 (en) | 2009-08-04 | 2015-04-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of The Health And Human Services, Centers For Disease Control And Prevention | Anti-RSV immunogens and methods of immunization |
US8883717B2 (en) * | 2012-03-30 | 2014-11-11 | Artificial Cell Technologies, Inc. | Antigenic compositions and methods |
-
2011
- 2011-07-07 EP EP11731610.9A patent/EP2590675B1/en active Active
- 2011-07-07 US US13/177,671 patent/US9487593B2/en active Active
- 2011-07-07 MX MX2012015030A patent/MX340796B/es active IP Right Grant
- 2011-07-07 CA CA2799934A patent/CA2799934C/en active Active
- 2011-07-07 RU RU2013101972A patent/RU2609661C2/ru active
- 2011-07-07 CN CN201180033742.9A patent/CN103037898B/zh active Active
- 2011-07-07 DK DK11731610.9T patent/DK2590675T3/en active
- 2011-07-07 WO PCT/US2011/043136 patent/WO2012006395A1/en active Application Filing
- 2011-07-07 CN CN201610369657.4A patent/CN106008716B/zh active Active
- 2011-07-07 ES ES11731610.9T patent/ES2688993T3/es active Active
- 2011-07-07 AU AU2011276251A patent/AU2011276251B2/en active Active
- 2011-07-07 JP JP2013518819A patent/JP5890407B2/ja active Active
- 2011-07-07 BR BR112013000345-6A patent/BR112013000345B1/pt active IP Right Grant
-
2012
- 2012-10-28 IL IL222723A patent/IL222723B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CN103037898A (zh) | 2013-04-10 |
AU2011276251A1 (en) | 2012-11-08 |
RU2609661C2 (ru) | 2017-02-02 |
AU2011276251B2 (en) | 2015-02-05 |
CA2799934C (en) | 2020-01-28 |
IL222723A0 (en) | 2012-12-31 |
JP5890407B2 (ja) | 2016-03-22 |
US20120009254A1 (en) | 2012-01-12 |
JP2013535428A (ja) | 2013-09-12 |
BR112013000345B1 (pt) | 2021-11-23 |
RU2013101972A (ru) | 2014-08-20 |
DK2590675T3 (en) | 2018-10-29 |
EP2590675B1 (en) | 2018-08-29 |
CN106008716A (zh) | 2016-10-12 |
IL222723B (en) | 2020-03-31 |
MX340796B (es) | 2016-07-27 |
ES2688993T3 (es) | 2018-11-07 |
US9487593B2 (en) | 2016-11-08 |
WO2012006395A1 (en) | 2012-01-12 |
AU2011276251A2 (en) | 2013-01-24 |
CN103037898B (zh) | 2016-06-29 |
CN106008716B (zh) | 2019-08-13 |
EP2590675A1 (en) | 2013-05-15 |
MX2012015030A (es) | 2013-06-13 |
CA2799934A1 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013000345A2 (pt) | composições antigênicas para vírus sincicial respiratório e métodos | |
BR112016028816A2 (pt) | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit. | |
CO2019000946A2 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos | |
BR112018074155A2 (pt) | anticorpo para lag-3, fragmento de ligação ao antígeno e aplicação farmacêutica do mesmo | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
UA114502C2 (uk) | Вакцина mycoplasma hyopneumoniae | |
BR112017002183A2 (pt) | conjugado, composição farmacêutica, e, método para aumentar uma resposta imune em um mamífero | |
BR112016027893A2 (pt) | molécula de ligação triespecífica, e, composição farmacêutica | |
CL2015001314A1 (es) | Anticuerpo de unión a tau; vector; célula hospedadora; hibridoma; péptido que comprende epítope de tau; composición farmacéutica que comprende al anticuerpo o al péptido de tau; dispositivo médico para administrarlos; y uso para tratar, prevenir o diagnosticar enfermedad de alzheimer o tautología relacionada (div. sol. n° 679-14). | |
BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
MX2016012124A (es) | Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos. | |
BR112015011389A2 (pt) | Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica | |
BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
CL2014000786A1 (es) | Composicion que comprende un péptido que se une de manera inmunoespecífica a la secuencia a relacionada con el polipeptido mhc de clase i (mica); método para obtener células inmunes dirigidas contra un antígeno propio de un individuo. | |
IN2014DN10288A (pt) | ||
MY185802A (en) | Antibody formulation | |
BR112013004288A2 (pt) | formas galênicas de múltiplos epítopos direcionados para indução de uma resposta imunológica a antigênios. | |
BR112016020009A2 (pt) | anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma | |
WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
MX350707B (es) | Composiciones antigenas y procedimientos. | |
BR112015031417A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 17/14 (2006.01), A61K 39/12 (2006.01), A61K 3 |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |